Veritas In Silico ＜130A＞ announced financial results for the 2nd quarter (24/1/6) of the fiscal year ending 2024/12 on the 5th. Business profit was 0.115 billion yen, operating loss was 0.066 billion yen, ordinary loss was 0.088 billion yen, and interim net loss was 0.09 billion yen. Since quarterly financial statements have not been prepared for the interim period ending 2024/12, the rate of increase or decrease for the interim period of the fiscal year ending 2024/12 compared to the interim period of the previous year is not described.
In the mRNA-targeted small molecule drug discovery business, we are utilizing the drug discovery platform ibVis (R) to promote joint drug discovery research with Toray ＜3402＞, Shionogi Pharmaceuticals＜4507＞, LaQuoria Drug Discovery ＜4579＞, and Takeda Pharmaceutical Industries ＜4502＞ (hereafter, these pharmaceutical companies are called “partners”), and the company's platform technology introduction etc. for domestic and international pharmaceutical companies interested in mRNA-targeted small molecule drug discovery We proceeded with the approach. We also promoted mRNA-related drug discovery efforts, including nucleic acid pharmaceuticals, for future business diversification. In the development of nucleic acid pharmaceuticals, the company has already identified antisense oligonucleotides (ASO), which are a type of nucleic acid drug that reduces the amount of mRNA in the p53 gene and suppresses protein expression, and along with obtaining patents within Japan, we are also proceeding with our own research activities to obtain ASO with even greater efficiency and activity. Also, from 2023/12, studies are underway with Mitsubishi Gas Chemical (4182) on the possibility of collaboration for the purpose of ASO research, development, and manufacturing.
During this interim accounting period, joint drug discovery research with each partner in the mRNA-targeted small molecule drug discovery business progressed smoothly, and results such as hit compound certification were achieved. In terms of earnings, business income from research support funds received regularly based on joint drug discovery research agreements and milestone income, etc. generated on a spot basis were recorded. 0.182 billion yen, including research and development expenses of 0.07 billion yen, was incurred in business expenses, resulting in operating losses.
As for the full-year earnings forecast for the fiscal year ending 2024/12, the initial plan is unchanged, with sales up 87.6% from the previous fiscal year to 0.676 billion yen, operating profit up 284.4% to 0.144 billion yen, ordinary profit up 257.6% to 0.128 billion yen, and net income up 229.0% to 0.108 billion yen.